Evaluation of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings

Introduction: Magnetic resonance imaging (MRI) can have a problem to delineate diffuse gliomas with an intact blood-brain barrier (BBB) especially when a marked peritumoral edema is present. We evaluated the potential of trans-1-amino-3-F-18-fluorocyclobutanecarboxylic acid (anti-F-18-FACBC) positron emission tomography (PET) to delineate the extent of diffuse gliomas by comparing PET findings with autoradiography, in vivo and ex vivo MRI, and histopathology findings. Methods: Dynamic PET was performed in rats with N-ethyl-N-nitrosourea-induced glioma for 60 min after anti-F-18-FACBC injection. Contrast-enhanced MRI was performed before or after PET. The PET images were fused with in vivo and ex vivo MR images, and histopathological images for direct comparisons. Autoradiograms were compared with the results of Evans Blue (EB) extravasation (to assess BBB integrity) and hematoxylin-eosin staining. Results: Histopathological examination, including EB extravasation assessment, and enhanced Ti-weighted MRI identified several diffuse gliomas with slight BBB disruption, similar to low-grade human gliomas. Anti-F-18-FACBC uptake was specific and high in the gliomas, irrespective of BBB integrity. Higher anti-F-18-FACBC uptake corresponded to areas of T2 hyperintensity, independent of gadolinium enhancement. Ex vivo autoradiography also showed high anti-F-18-FACBC accumulation in tumors lacking EB extravasation and a correlation between anti-F-18-FACBC accumulation and tumor cell density, but not EB extravasation. Conclusions: Anti-F-18-FACBC-PET allowed visualization of gliomas irrespective of BBB integrity. The tumor-to-normal uptake ratio of anti-F-18-FACBC generally correlated with the relative cell density. Anti-F-18-FACBC PET combined with MRI shows promise for preoperative glioma delineation. Advances in knowledge: Radiopharmaceuticals that cross the BBB, such as anti-F-18-FACBC, are taken up by low-grade gliomas with equivocal MRI findings due to an intact BBB. Implications for patient care: Surgery is the first-line therapy for low-grade gliomas; therefore, delineation of their extent in the presence of an intact BBB is essential to planning surgery that removes the entire neoplasm, which will positively affect long-term survival. (C) 2015 Elsevier Inc. All rights reserved.